Novo Nordisk India unveils oral Semaglutide to treat diabetes
Drug firm Novo Nordisk India on Thursday said it has launched a first of its kind diabetes treatment medication in the country. The company said it has introduced the world's first and only oral semaglutide, a game-changer in diabetes management.
Semaglutide, a GLP-1 receptor analogue (GLP-1 RA) - one of the drug classes to treat diabetes, till now was available only in the form of injections and this is the first time such medication has been developed in an oral form.
For more information, check out the full story on the link below: